Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma.
Publication
, Preprint
Stauffer, PE; Brinkley, J; Jacobson, D; Quaranta, V; Tyson, DR
April 1, 2024
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Stauffer, P. E., Brinkley, J., Jacobson, D., Quaranta, V., & Tyson, D. R. (2024). Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma. https://doi.org/10.1101/2023.11.03.565532
Stauffer, Philip E., Jordon Brinkley, David Jacobson, Vito Quaranta, and Darren R. Tyson. “Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma.,” April 1, 2024. https://doi.org/10.1101/2023.11.03.565532.
Stauffer PE, Brinkley J, Jacobson D, Quaranta V, Tyson DR. Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma. 2024.
Stauffer, Philip E., et al. Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma. 1 Apr. 2024. Pubmed, doi:10.1101/2023.11.03.565532.
Stauffer PE, Brinkley J, Jacobson D, Quaranta V, Tyson DR. Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma. 2024.